Chimeric Therapeutics Competitors and Similar CompaniesClear all
Chimeric Therapeutics's competitors and similar companies include Spur Therapeutics and Polyplus-transfection.
 Spur Therapeutics Spur Therapeutics (formerly known as Freeline) is a clinical-stage biotechnology company that develops transformative gene therapies. |  Polyplus-transfection Polyplus-transfection is a biotechnology company that develops and sells innovative solutions for the delivery of nucleic acids in research, bioproduction, and therapeutics. | ||
Founding Date | Founding Date 2020 | Founding Date 2015 | Founding Date 2002 |
Type | Type Public | Type Subsidiary | Type Private |
Tags | |||
Locations | Locations Carlton, AU HQ | Locations Stevenage, GB HQ Boston, US New York, US | Locations Illkirch-Graffenstaden, FR HQ New York, US |
Employees | Employees N/A | Employees 122 | Employees 1133% increase |
Financial | |||
Revenue (est.) | Revenue (est.) $4m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods $847k (FY, 2025) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $11.7m (FY, 2025) | Gross profit $8.9m (FY, 2022) | Gross profit N/A |
Net income | Net income ($10.4m) (FY, 2025) | Net income ($89m) (FY, 2022) | Net income N/A |
Funding | |||
Total funding raised | Total funding raised N/A | Total funding raised $ 289.3m | Total funding raised $ 3.2m |
For sources of this data, please see the company profile
View Company Profiles
Spur Therapeutics
HQ
Stevenage, GB
Spur Therapeutics (formerly known as Freeline) is a clinical-stage biotechnology company that develops transformative gene therapies.
View companyPolyplus-transfection
HQ
Illkirch-Graffenstaden, FR
Employees
113↑ 3% increase
Polyplus-transfection is a biotechnology company that develops and sells innovative solutions for the delivery of nucleic acids in research, bioproduction, and therapeutics.
View company